Enroll in Research > Research Search & Enroll Tool > Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations
Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

Clinicaltrials.gov identifier:
NCT02286687

Treatment:
Breast, Ovarian, Pancreatic, Prostate

Study Contact Information:

Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930 or email 


Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

About the Study

This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes.

Type of Study

This is an open-label, single arm study.

  • In an open-label study, participants will know which medication they are receiving.     
  • In a single-group assignment study, all study participants will receive the same therapy.

What the Study Entails

  • Participants will receive talazoparib orally once per day. Participants will remain on the medication as long as their cancer doesn't progress and they don't experience unacceptable side effects. 
  • Participants are followed up at 30 days and then every 12 weeks for 1 year.

Study Site

Houston, TX
M D Anderson Cancer Center
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930     

This Study is Open To:

Men and women age 18 years and older can be considered for enrollment in this study if they:

  • Have advanced or metastatic cancer that is not responding to standard therapy or has relapsed after standard therapy
  • Have one of the following:
    • Tumor tissue that shows mutations in BRCA1 or BRCA2 genes, or
    • Tumor tissue that shows mutations in ATM, PALB2 or other genes
    • inherited mutation in BRCA1 or BRCA2 genes (and not breast or ovarian cancer)
  • Have tumor tissue that can be biopsied and that shows gene mutations in the tumor; patients with an inherited mutation in BRCA1 or BRCA2 genes can be enrolled in this study without undergoing biopsy and tumor testing.
This Study is Not Open To:

People with the following are not eligible for the study:

  • Had prior treatment with a PARP inhibitor
  • Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
  • Heart condition such as a cerebrovascular accident (CVA), myocardial infarction or unstable angina within previous 6 months
  • A known additional malignancy that is progressing or requires active treatment
  • Known active central nervous system (CNS) metastases and/or meningeal cancer